In the treatment of diabetes, one strategy is the development of selective PPARγ modulators, SPPARMs, to preserve the expression level of PPARγ in vivo and regulate the transcription of therapeutic-related target genes while avoiding the regulation of target genes linked to adverse reactions [73]. Here, PPARG is linked to diabetes mellitus.